Poolbeg Pharma has been granted a patent in the United States for the treatment of hypercytokinaemia using its new influenza drug POLB 001.
The US patent covers the use of POLB 001 and related p38 MAP kinase inhibitors for the treatment of “cytokine storm”, including hypercytokinaemia that occurs because of a viral infection, cancer or autoimmune response by reducing the body’s hyperinflammatory response.
POLB 001 is a viral strain agnostic, small molecule immunomodulator being developed to address severe influenza and other acute inflammatory conditions.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
